The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME.
Prospective, randomized cross-over clinical trial METHODS: Twenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral domain-optical coherence tomography (SD-OCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Cross-over at week 16 provided changes in protein levels after each intervention in all 20 patients.
After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including three known PPFs, angiopoietin-2 (r=0.40, p=0.001), hepatocyte growth factor (HGF, r=0.31, p=0.02), and endocrine gland-VEGF (EG-VEGF, r=0.43, p<0.001). Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reduction after injection of a VEGF-neutralizing protein as well as dexamethasone implant suggesting their modulation is likely secondary to changes in edema rather than causative.
Correlation of edema reduction with reduction in the PPFs angiopoietin-2, HGF, and EG-VEGF provides potential insight into the multi-factorial molecular mechanism by which dexamethasone implants reduce edema and suggest that additional study is needed to investigate the contributions of these 3 factor to chronic DME.
Pharmacology, Toxicology and Pharmaceutical Science
4
5%
Agricultural and Biological Sciences
2
2%
Other
6
7%
Unknown
26
31%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 July 2016.
All research outputs
#4,295,221
of 32,567,093 outputs
Outputs from American Journal of Ophthalmology
#743
of 8,405 outputs
Outputs of similar age
#52,349
of 328,665 outputs
Outputs of similar age from American Journal of Ophthalmology
#8
of 106 outputs
Altmetric has tracked 32,567,093 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,405 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,665 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.
